Skip to content
Syenza News
  • Innovative Tech
  • Diseases
  • Health Policy
  • HTA
  • Data Analysis
  • Clinical Practice
  • Contributors
BACK TO MAIN SITE

MR-107A-02: Revolutionizing Non-Opioid Pain Man...

By Rene Pretorius

May 12, 2025

Viatris Inc.
Prevention Valuation: Fund Health, Not Just Savings
FDA AI Drug Approval
Implementing Health Technology Assessment in Oman
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Empowering Health: The Role of Self-Care and NCDs in Global Health Policy
Nipocalimab for Myasthenia Gravis Treatment
Journavx for Pain Management: Toward Affordability and Access
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
« Previous 1 … 8 9 10 11 12 … 45 Next »

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER

This is required.
This is required.
This is required.

SERVICES

  • HEOR
  • Global Market Access
  • Dynamic Intelligence
  • Glossary of Terms
  • Advanced Degrees

QUICK LINKS

  • About
  • Case Studies
  • Insights
  • Art of Science
  • Careers
  • Contact Us
  • Copyright Notice
  • Privacy Policy
  • Terms & Conditions
schedule a meeting
LINKEDIN
TWITTER
© 2026 Syenza™. All rights reserved.

Made with heart by Frogiez

schedule a meeting